What can molecular pathology contribute to the management of renal cell carcinoma?

Nature Reviews Urology

Volumn 8, Issue 5, 2011, Pages 255-265

  Stewart, Grant D ^a   O'Mahony, Fiach C ^a   Powles, Thomas ^b   Riddick, Antony C P ^a   Harrison, David J ^a   Faratian, Dana ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC AGENT; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; TUMOR MARKER;

ANEMIA; BLOOD PRESSURE VARIABILITY; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RELAPSE; CRYOTHERAPY; DEPRESSION; DIARRHEA; FATIGUE; FEVER; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; MOLECULAR PATHOLOGY; NAUSEA; NEUTROPENIA; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEQUENCE ANALYSIS; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

ANIMALS; CARCINOMA, RENAL CELL; DISEASE MANAGEMENT; GENE EXPRESSION PROFILING; GENE TARGETING; GENE THERAPY; HUMANS; KIDNEY NEOPLASMS; PATHOLOGY, MOLECULAR; TUMOR MARKERS, BIOLOGICAL;

EID: 79955802498     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.43     Document Type: Review

References (114)

1. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
2. Cancer Research UK. Kidney cancer statistics [online] http://info.cancerresearchuk.org/cancerstats/types/kidney/(2011).
3. Linehan, W. M. et al. Molecular diagnosis and therapy of kidney cancer. Annu. Rev. Med. 61, 329-343 (2010).
4. Jayson, M. & Sanders, H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 51, 203-205 (1998). (Pubitemid 28093168)
5. Hollingsworth, J. M., Miller, D. C., Daignault, S. & Hollenbeck, B. K. Rising incidence of small renal masses: a need to reassess treatment effect. J. Natl Cancer Inst. 98, 1331-1334 (2006). (Pubitemid 44530728)
6. Nguyen, M. M., Gill, I. S. & Ellison, L. M. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. J. Urol. 176, 2397-2400 (2006). (Pubitemid 44755062)
7. Chow, W. H., Devesa, S. S., Warren, J. L. & Fraumeni, J. F. Jr. Rising incidence of renal cell cancer in the United States. JAMA 281, 1628-1631 (1999). (Pubitemid 29211773)
8. Touijer, K. et al. The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur. Urol. 57, 214-222 (2010).
9. Heuer, R. et al. A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur. Urol. 57, 223-232 (2010).
10. Chin, A. I., Lam, J. S., Figlin, R. A. & Belldegrun, A. S. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev. Urol. 8, 1-7 (2006).
11. Levy, D. A., Slaton, J. W., Swanson, D. A. & Dinney, C. P. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J. Urol. 159, 1163-1167 (1998). (Pubitemid 28172785)
12. Chae, E. J., Kim, J. K., Kim, S. H., Bae, S. J. & Cho, K. S. Renal cell carcinoma: analysis of postoperative recurrence patterns. Radiology 234, 189-196 (2005).
13. Ljungberg, B. et al. Renal cell carcinoma guideline. Eur. Urol. 51, 1502-1510 (2007). (Pubitemid 46634775)
14. Cutress, M. L., Ratan, H. L., Williams, S. T. & O'Brien, M. F. Update on the management of T1 renal cortical tumours. BJU Int. 106, 1130-1136 (2010).
15. Vaishampayan, U. Metastatic renal cancer: a review of current and future treatment options. Am. J. Cancer 2, 201-210 (2003). (Pubitemid 36876617)
16. Flanigan, R. C. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655-1659 (2001). (Pubitemid 33126820)
17. Di Lorenzo, G., Autorino, R. & Sternberg, C. N. Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur. Urol. 56, 959-971 (2009).
18. McDermott, D. F. et al. The high-dose aldesleukin (HD IL-2) Select trial in patients with metastatic renal cell carcinoma (mRCC): preliminary assessment of clinical benefit. Presented at the ASCO 2010 Genitourinary Cancers Symposium.
19. Rini, B. I. & Flaherty, K. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol. Oncol. 26, 543-549 (2008).
20. Swanton, C. et al. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med. 2, 53 (2010).
21. De, P. & Leyland-Jones, B. Whither HER2-related therapeutics? J. Clin. Oncol. 28, 1091-1096 (2010).
22. Lord, C. J. & Ashworth, A. Biology-driven cancer drug development: back to the future. BMC Biol. 8, 38 (2010).
23. Wang, W. L. et al. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother. Pharmacol. 67 (Suppl. 1), S15-S24 (2011).
24. Rosner, I., Bratslavsky, G., Pinto, P. A. & Linehan, W. M. The clinical implications of the genetics of renal cell carcinoma. Urol. Oncol. 27, 131-136 (2009).
25. Renshaw, A. A. & Richie, J. P. Subtypes of renal cell carcinoma. Different onset and sites of metastatic disease. Am. J. Clin. Pathol. 111, 539-543 (1999). (Pubitemid 29153152)
26. Banumathy, G. & Cairns, P. Signaling pathways in renal cell carcinoma. Cancer Biol. Ther. 10, 658-664 (2010).
27. Verine, J. et al. Hereditary renal cancer syndromes: an update of a systematic review. Eur. Urol. doi:10.1016/j.eururo.2010.08.031.
28. Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277-285 (2010).
29. Beroukhim, R. et al. Patterns of gene expression and copy-number alterations in von Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 69, 4674-4681 (2009).
30. Stolle, C. et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum. Mutat. 12, 417-423 (1998). (Pubitemid 28512618)
31. Cohen, H. T. & McGovern, F. J. Renal-cell carcinoma. N. Engl. J. Med. 353, 2477-2490 (2005). (Pubitemid 41770167)
32. Arsanious, A., Bjarnason, G. A. & Yousef, G. M. From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. Mol. Cancer 8, 20 (2009).
33. Boer, J. M. et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res. 11, 1861-1870 (2001). (Pubitemid 33100427)
34. Takahashi, M. et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc. Natl Acad. Sci. USA 98, 9754-9759 (2001). (Pubitemid 32769376)
35. Jones, J. et al. Gene signatures of progression and metastasis in renal cell cancer. Clin. Cancer Res. 11, 5730-5739 (2005). (Pubitemid 41170297)
36. Lenburg, M. E. et al. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 3, 31 (2003).
37. Yao, M. et al. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J. Pathol. 205, 377-387 (2005). (Pubitemid 40253927)
38. Takahashi, M. et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 22, 6810-6818 (2003). (Pubitemid 37372221)
39. Sultmann, H. et al. Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin. Cancer Res. 11, 646-655 (2005). (Pubitemid 40116891)
40. Young, A. N. et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am. J. Pathol. 158, 1639-1651 (2001). (Pubitemid 32422929)
41. Higgins, J. P. Gene array studies in renal neoplasia. ScientificWorldJournal 6, 502-511 (2006). (Pubitemid 43760955)
42. Ficarra, V. et al. prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur. Urol. doi:10.1016/j.eururo.2010.08.001.
43. Young, A. N. et al. Beta defensin-1, parvalbumin, and vimentin: a panel of diagnostic immunohistochemical markers for renal tumors derived from gene expression profiling studies using cDNA microarrays. Am. J. Surg. Pathol. 27, 199-205 (2003). (Pubitemid 36152229)
44. Pan, C. C., Chen, P. C. & Ho, D. M. The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases. Histopathology 45, 452-459 (2004). (Pubitemid 39524319)
45. Liu, L. et al. Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch. Pathol. Lab. Med. 131, 1290-1297 (2007). (Pubitemid 47257641)
46. Allory, Y. et al. Profiling and classification tree applied to renal epithelial tumours. Histopathology 52, 158-166 (2008).
47. Bui, M. H. et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802-811 (2003). (Pubitemid 36182618)
48. Perret, A. G., Clemencon, A., Li, G., Tostain, J. & Peoc'h, M. Differential expression of prognostic markers in histological subtypes of papillary renal cell carcinoma. BJU Int. 102, 183-187 (2008). (Pubitemid 351852599)
49. Moch, H. et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am. J. Pathol. 154, 981-986 (1999). (Pubitemid 29169731)
50. Liao, S. Y., Aurelio, O. N., Jan, K., Zavada, J. & Stanbridge, E. J. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 57, 2827-2831 (1997). (Pubitemid 27315020)
51. Liou, L. S. et al. Microarray gene expression profiling and analysis in renal cell carcinoma. BMC Urol. 4, 9 (2004).
52. Gieseg, M. A. et al. Expression profiling of human renal carcinomas with functional taxonomic analysis. BMC Bioinformatics 3, 26 (2002).
53. Brannon, A. R. et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 1, 152-163 (2010).
54. Kosari, F. et al. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin. Cancer Res. 11, 5128-5139 (2005). (Pubitemid 41003697)
55. Skubitz, K. M. & Skubitz, A. P. Differential gene expression in renal-cell cancer. J. Lab. Clin. Med. 140, 52-64 (2002). (Pubitemid 34703347)
56. Vasselli, J. R. et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc. Natl Acad. Sci. USA 100, 6958-6963 (2003). (Pubitemid 36706375)
57. Zhao, H. et al. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med. 3, e13 (2006).
58. Eichelberg, C., Junker, K., Ljungberg, B. & Moch, H. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur. Urol. 55, 851-863 (2009).
59. Vickers, M. M. & Heng, D. Y. Prognostic and predictive biomarkers in renal cell carcinoma. Target Oncol. 5, 85-94 (2010).
60. Hacker, K. E. & Rathmell, W. K. Emerging molecular classification in renal cell carcinoma: implications for drug development. Target Oncol. 5, 75-84 (2010).
61. Lam, J. S., Pantuck, A. J., Belldegrun, A. S. & Figlin, R. A. Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials. Clin. Cancer Res. 13, 703s-708s (2007).
62. Yao, M. et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl Cancer Inst. 94, 1569-1575 (2002). (Pubitemid 35277281)
63. Schraml, P. et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J. Pathol. 196, 186-193 (2002). (Pubitemid 34110900)
64. Baldewijns, M. M. et al. Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene. Cell Oncol. 31, 371-382 (2009).
65. Choueiri, T. K. et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J. Urol. 180, 860-866 (2008).
66. Cho, D. et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 5, 379-385 (2007). (Pubitemid 47584475)
67. Rini, B. I. et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 98, 756-762 (2006). (Pubitemid 44368020)
68. Kim, J. H. et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol. Rep. 13, 859-864 (2005).
69. Klatte, T. et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin. Cancer Res. 13, 7388-7393 (2007).
70. Lidgren, A. et al. Hypoxia-inducible factor 1 alpha expression in renal cell carcinoma analyzed by tissue microarray. Eur. Urol. 50, 1272-1277 (2006). (Pubitemid 44692925)
71. Jacobsen, J., Rasmuson, T., Grankvist, K. & Ljungberg, B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J. Urol. 163, 343-347 (2000).
72. Na, X. et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J. Urol. 170, 588-592 (2003). (Pubitemid 36870265)
73. Escudier, B. et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27, 3312-3318 (2009).
74. Rini, B. I. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 26, 3743-3748 (2008).
75. Porta, C. et al. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int. 77, 809-815 (2010).
76. Sabatino, M. et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J. Clin. Oncol. 27, 2645-2652 (2009).
77. Escudier, B. J. et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis [abstract 5025]. J. Clin. Oncol. 26 (Suppl.) (2008).
78. Lam, J. S., Leppert, J. T., Figlin, R. A. & Belldegrun, A. S. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 66, 1-9 (2005). (Pubitemid 41356552)
79. Leibovich, B. C. et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J. Clin. Oncol. 25, 4757-4764 (2007). (Pubitemid 350086478)
80. Atkins, M. et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 11, 3714-3721 (2005). (Pubitemid 40685588)
81. Pantuck, A. J. et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109, 2257-2267 (2007). (Pubitemid 46801555)
82. Klatte, T. et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol. Biomarkers Prev. 18, 894-900 (2009).
83. Kim, H. L. et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin. Cancer Res. 10, 5464-5471 (2004). (Pubitemid 39100484)
84. McShane, L. M. et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Clin. Pract. Urol. 2, 416-422 (2005). (Pubitemid 43115010)
85. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005). (Pubitemid 41464705)
86. Faratian, D., Clyde, R. G., Crawford, J. W. & Harrison, D. J. Systems pathology\taking molecular pathology into a new dimension. Nat. Rev. Clin. Oncol. 6, 455-464 (2009).
87. Tsao, M. S. et al. Erlotinib in lung cancer\molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133-144 (2005).
88. Faratian, D. et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res. 69, 6713-6720 (2009).
89. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
90. Meylan, E. et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462, 104-107 (2009).
91. Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239 (2009).
92. Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
93. Kan, Z. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869-873 (2010).
94. Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363 (2010).
95. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542 (2011).
96. Duns, G. et al. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res. 70, 4287-4291 (2010).
97. Dhillon, J. et al. Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change. Am. J. Surg. Pathol. 33, 44-49 (2009).
98. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010).
99. Huang, D. et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 70, 1053-1062 (2010).
100. Stewart, G. D. et al. The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int. 105, 8-13 (2010).
101. Faratian, D., Langdon, S. P. & Harrison, D. J. How can systems pathology help us personalize cancer therapy? Discov. Med. 8, 81-86 (2009)
102. Sunitinib malate before and after surgery in treating patients with previously untreated metastatic kidney cancer [online], http://clinicaltrials. gov/ct2/show/NCT01024205 (2011).
103. Gonzalez-Angulo, A. M., Hennessy, B. T. & Mills, G. B. Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol. 28, 2777-2783 (2010).
104. Malhotra, D. et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 38, 5718-5734 (2010).
105. Faratian, D., Bown, J. L., Smith, V. A., Langdon, S. P. & Harrison, D. J. Cancer systems biology. Methods Mol. Biol. 662, 245-263 (2010).
106. Faratian, D. et al. Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy. Eur. J. Cancer doi:10.1016/j.ejca.2011.01.014.
107. Delahunt, B., Bethwaite, P. B., Thornton, A. & Ribas, J. L. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling. Correlation with clinical outcome. Cancer 75, 2714-2719 (1995).
108. Rioux-Leclercq, N. et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 55, 501-505 (2000). (Pubitemid 30157952)
109. Visapaa, H. et al. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology 61, 845-850 (2003). (Pubitemid 36384994)
110. Bui, M. H. et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J. Urol. 171, 2461-2466 (2004). (Pubitemid 38625515)
111. Zigeuner, R., Ratschek, M., Rehak, P., Schips, L. & Langner, C. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology 63, 651-655 (2004). (Pubitemid 38479402)
112. Thompson, R. H. et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66, 3381-3385 (2006).
113. Kallakury, B. V. et al. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin. Cancer Res. 7, 3113-3119 (2001). (Pubitemid 32963832)
114. Huang, D. et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70, 1063-1071 (2010).